Physician profile
Renu Soni
NPI 1982601779
$6,227.34
in general payments reported to CMS, 2019-2025
44 companies · $897 in 2025
The $897 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $497 · 2020: $406 · 2021: $841 · 2022: $1,016 · 2023: $1,489 · 2024: $1,082 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,968 · Education: $499.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,968.40 |
| Education | $499.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $876.24 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $550.22 | 2019-2025 | |
| Seagen INC. | $503.84 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Astellas Pharma US INC | $330.81 | 2020-2025 | Padcev, Vyloy, Xospata |
| Janssen Biotech, INC. | $296.15 | 2019-2025 | Darzalex, Rybrevant, Talvey |
| Celgene Corporation | $284.38 | 2019-2025 | Reblozyl, Opdualag |
| Amgen INC. | $279.56 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Gilead Sciences, INC. | $246.05 | 2022-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $218.09 | 2019-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Array Biopharma INC | $190.53 | 2021-2025 | Braftovi, Mektovi, Lorbrena |
| E.R. Squibb & Sons, L.L.C. | $168.44 | 2019-2024 | Augtyro |
| Pfizer INC. | $165.77 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $141.14 | 2020-2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $134.80 | 2020-2025 | Enhertu, Imfinzi |
| Taiho Oncology, INC. | $130.95 | 2019-2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renu Soni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.